Yahoo Web Search

    • ADDF STATEMENT ON GANTENERUMAB DATA PRESENTED AT CTAD

      Morningstar· 3 days ago

      The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer's will require ...

  1. Related searches

    free data science class